AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 91 min read$BLFS

Ellingson Rachel sold (to issuer) 57,995 shares of BLFS

Ellingson Rachel sold (to issuer) 57,995 shares of BIOLIFE SOLUTIONS INC (BLFS) on 2026-10-06.

Original reporting
SEC EDGAR · Ellingson Rachel
Published Oct 9, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLFS
Bearish
medium confidence
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLFSBearishLow
01

Why it matters

The filing provides new insider transaction data but limited market impact due to modest size and lack of price details.

02

Market read

New insider sale information adds modest insight for BLFS investors, with low immediate trading relevance.

03

What to watch

Absence of price information makes it hard to gauge dollar magnitude; the director may have tax or liquidity motives.

Relevance 4/10Novelty 5/10Timing: today

Background

The article reports a Form 4 filing by a director of Biolife Solutions, disclosing an insider share sale.

Company-level read

Ticker impact

$BLFSBearishMedium confidence
Context

Director Rachel Ellingson sold 57,995 shares of Biolife Solutions (BLFS) on 2026-10-06.

Expected impact

potential slight downward pressure as the market prices the insider sale

Evidence & confidence

Director sale suggests possible lack of confidence, yet the transaction is relatively small and price undisclosed.

Market effects

Sector

Minimal impact on the healthcare services sector; insider activity is routine.

Regional

No notable regional effect; confined to the company's shareholders.

Global

Limited global relevance; only affects BLFS investors.

Counterpoint

What could challenge this read

The sale could be a strategic rebalancing rather than a lack of confidence, so price impact may be negligible.

Key entities

  • company
    Biolife Solutions Inc.

    US-listed biotech firm (ticker BLFS) whose director sold shares.

  • person
    Rachel Ellingson

    Director of Biolife Solutions who sold 57,995 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLFS insider trading history →

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min
SEP 4
$RGENMedAI 8/10

[DEFM14A] BIOLIFE SOLUTIONS INC Merger Proxy Statement

BioLife Solutions (BLFS) filed a proxy statement for a merger with Repligen. The deal offers $11.25 and 0.1442 Repligen shares per BioLife share, pending stockholder approval on October 5, 2026. BioLife stock will be delisted if the merger completes. Repligen's share count will increase, diluting existing holders.

stocktitan.net2 min